I imagine mass spectrometry playing a bigger role in daily healthcare. Already crucial for neonatal screening and bacterial identification, I envision a shift from targeted methods to untargeted whole proteome analysis in clinical settings. By tracking an individual’s proteome over time, mass spectrometry could serve as a biological diary, collecting thousands of proteoforms, to detect deviations from baseline in support of early diagnosis or treatment decisions. Achieving this will require mass spec to become smaller, faster, cheaper, and more user-friendly, as well as advanced informatics tools to integrate omics, clinical data for each patient for personalized care.